Page 75 - CIBERES-2015-eng

Most relevant scientific articles
Research Groups
Pozo-roDríguez F, Castro-aCosta a, aLvarez CJ, LóPez-CaMPos JL, Forte a, LóPez-quiLez a et aL. Determi- nants of between-hospital variations in outcomes for pa- tients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUDIPOC) in Spain.International journal of clinical practice. 2015;.
Faner r., gutierrez-saCristan a., Castro-aCosta a., grosDiDier s., gan W., sánChez-Mayor M. et aL. Mo- lecular and clinical diseasome of comorbidities in exac-
gaLiè n, huMBert M, vaChiery JL, giBBs s, Lang i, torBiCKi a et aL. 2015 ESC/ERS Guidelines for the diagnosis and treat- ment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for Eu- ropean Paediatric and Congenital Cardiology (AEPC), Inter- national Society for Heart and Lung Transplantation (ISHLT). The European respiratory journal. 2015;46(4):903-75.
erbated COPD patients. European Respiratory Journal. 2015;46(4):1001-1010.
PaesMans M., garCía C., Wong C.-y.o., Patz e.F., KoMaKi r., esChMann s. et aL. Primary tumour standardised up- take value is prognostic in nonsmall cell lung cancer: A multivariate pooled analysis of individual data. European Respiratory Journal. 2015;46(6):1751-1761.
Highlights
The Group 21 CIBERES-imas12 Respiratory Disease, has updated its working hypothesis, and incorporated new lines of research and projects to traditional bron- chogenic cancer and COPD.
Scientific focus: Study of determinants of health condi- tions in patients with respiratory diseases and clinical implications for the evaluation and update of action, identification of biomarkers (diagnostic, prognostic and therapeutic), new therapeutic options, quality im- provement and optimization assistance protocols .
Main lines and task in 2015:
LUNG AND PLEURA CANCER: To identified a set of clinical-molecular variables that improve the prog- nostic and predictive TNM and clinical translation of results.
-Collaboration generation and initial analysis of data- base knowledge clinical molecular lung cancer stages I and IIs.
-Generation and maintenance Cohort resected cancer early.
COPD: To studied clinical, biological, microbiological, radiological, functional determinants of progression and severity. To evaluated the impact of different
sánChez-De-La-torre M., KhaLyFa a., sánChez-De-La- torre a., Martínez-aLonso M., Martínez-garCía M.a., BarCeLo a. et aL. Precision Medicine in Patients With Re- sistant Hypertension and Obstructive Sleep Apnea Blood Pressure Response to Continuous Positive Airway Pres- sure Treatment. Journal of the American College of Cardi- ology. 2015;66(9):1023-1032.
health care approaches in the management of disease activity.
-Participation COPD study EARLY (Determinants of the onset and progression of COPD in young adults) and BI- OMCOPD (biomarkers and personalized clinical profiles in Chronic Obstructive Pulmonary Disease).
-Coordination DELICATO study (local Design and Imple- mentation of clinical audits in different types of OLD).
-Updating and publishing new results CEPA (Spanish Cohort advanced COPD).
-Further analysis and publication AUDIPOC Spain AUDI- POC Europe 2008 and 2011.
-Participation planning next European Auditing.
PULMONARY HYPERTENSION: To established com- plementary network of research to identify new mark- ers of activity and new therapeutic targets on Lung Hy- pertension, with clinical vocation.
-Participation EMPATHY project (New Markers and Therapeutic Targets for the Diagnosis and Treatment of Pulmonary Hypertension)
LUNG TRANSPLANT: To Collaborate with BIOBANK CIBERES
Institution: Hospital Universitrio 12 de Octubre · Contact: Av de Cordoba S/N 28041
Centro de Actividades Ambulatorias I+12 6a Planta Bloque D Pasillo 1. 28041 Madrid · Tel.: 91 779 28 68 E.mail: [email protected] · Web: http://imas12.h12o.es/index.php/areas-de-investigacion
CIBERES I Annual report 2015 I 75